DNA CHARCOAL PLASMA SORPTION FOR TREATMENT OF SLE

描述：(改编自申请人的摘要)长期 本方案的目的是开发一种基于 系统性红斑狼疮(SLE)等免疫学疾病的治疗 精神错乱。系统性红斑狼疮的一个决定性特征是血液中存在 抗DNA抗体(Ab)，其水平与 疾病症状的严重程度。目前的治疗方法略微有效。 或者受到严重副作用的限制。生物-DT基吸附剂 血液透析系统已被证明在治疗肝功能衰竭方面有效。 昏迷。这项技术通过将其与PF相结合而得到增强 一种辅助系统，允许直接处理等离子体 用于去除大分子或蛋白质结合分子的粉末状吸附剂。DNA的使用 生物DTPF的PF单元中的免疫吸附剂将提供一种治疗方法 系统性红斑狼疮急性加重期的血液学表现 降低抗DNA抗体水平。DNA将被结合到活性碳上 已经使用伽马辐射用三氯乙烯基硅烷进行了底漆，以及 使用标准方法进行量化。DNA-木炭结合能力的研究 从纯化的蛋白溶液或血清中提取的抗DNA单抗将 用ELISA法测定。DNA的流变性- 炭悬浮液在PF吸附中对其性能的影响 还将对系统进行评估。 建议的商业应用： 系统性红斑狼疮(SLE)是一种慢性、复发性免疫疾病 疾病，其严重程度与抗DNA抗体水平有关。 狼疮基金会估计，大约有140万美国人 患有系统性红斑狼疮，75%的患者将经历严重的 可能可以用DNA免疫吸附来治疗。DNA免疫吸附具有 通过以下方式降低这些患者的发病率和器官损害的可能性 减少或消除抗DNA抗体，并可能避免 需要有严重毒副作用的药物治疗。

DESCRIPTION: (Adapted from the applicant's abstract) The long-term objective of this proposal is to develop an extracorporeal sorbent based treatment for systemic lupus erythematosus (SLE) and other immunologic disorders. A defining feature of SLE is the presence in the blood of anti-DNA antibodies (Ab), the level of which is correlated with the severity of disease symptoms. Current treatments are marginally effective or limited by severe side effects. The BioLogic-DT sorbent-based hemodialysis system has proven useful in the treatment of liver failure with coma. This technology has been enhanced by combining it with a PF auxiliary system which permits the direct treatment of plasma with powdered sorbents to remove large or protein bound molecules. Use of DNA immunosorbent in the PF unit of the BioLogic-DTPF will provide a therapy for the hematologic manifestations of acute exacerbations of SLE while reducing the anti-DNA Ab level. DNA will be bound to activated charcoal which has been primed with trichlorovinylsilane using gamma radiation, and quantified using standard methods. The capacity of DNA-charcoal to bind monoclonal anti-DNA Ab from purified protein solution or serum will be determined using an ELISA method. The rheologic properties of the DNA- charcoal suspension affecting its behavior in the PF sorbent pumping system will also be evaluated. PROPOSED COMMERCIAL APPLICATION: Systemic lupus erythematosus (SLE) is a chronic, relapsing immune disorder, the severity of which is linked to anti-DNA antibody levels. The Lupus Foundation estimates that approximately 1.4 million Americans have SLE, and that 75% of patients will experience severe episodes which may be treatable with DNA immunoadsorption. DNA immunoadsorption has the potential to reduce morbidity and organ damage in these patients by reducing or eliminating the anti-DNA antibodies and possibly obviating the need for drug therapies with severe toxic side effects.